A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Chronic Kidney Disease (CKD)

In brief

The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA. The study is looking at several other research questions, including: * Side effects that may be experienced from taking vonsetamig * How vonsetamig works in the body * How much vonsetamig is present in the blood * If vonsetamig works to lower levels of antibodies to HLA

Key facts

Study ID: NCT05092347
Run by: Regeneron Pharmaceuticals
People needed: 43
Starts: 2022-08-02
Expected to finish: 2027-11-22
Last updated by the study team: 2026-06-02

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Cedars-Sinai Medical Center — Los Angeles, California, United States
University of California Irvine — Orange, California, United States
Connie Frank Transplant Center at UCSF — San Francisco, California, United States
Yale University of Medicine — New Haven, Connecticut, United States
Medstar Georgetown Transplant Institute - 2-PHC — Washington D.C., District of Columbia, United States
Comprehensive Transplant Center — Chicago, Illinois, United States
John Hopkins Hospital — Baltimore, Maryland, United States
University of Minnesota — Minneapolis, Minnesota, United States
New York University Langone Health — New York, New York, United States
Penn Transplant Institute — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.